HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders
Advertisement
HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases.
The partnership addresses a high unmet need in cardiovascular health. Genetic cardiomyopathies - including hypertrophic, dilated, and arrhythmogenic forms - are a leading cause of heart failure and sudden cardiac death, particularly among younger individuals. Across major pharmaceutical markets (US, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan), approximately one million people are affected, many of whom face limited treatment options and a high burden of disease.
“Inherited heart diseases often strike early and progress silently. By modeling genetic cardiomyopathies in human cardiac organoids, we can screen and profile potential therapies with unprecedented precision and speed,” said Michael Krebs, CEO of HeartBeat.bio.“ This collaboration with Boehringer Ingelheim marks an important step towards bringing new, transformative treatments to patients with inherited heart conditions.”
HeartBeat.bio’s Cardioid Drug Discovery Platform uses chamber-like cardiac organoids derived from induced pluripotent stem cells (iPSCs) to replicate key features of inherited heart diseases. The platform has demonstrated translational relevance in pilot studies, including its applicability for adeno-associated virus (AAV) pharmacological experiments.
This collaboration builds on a long-standing relationship between the two companies. Boehringer Ingelheim has previously contributed to the development of the Cardioid platform by providing pharmaceutical R&D expertise, shaping disease-relevant screening assays, and supplying benchmark compounds for validation.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.